CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment

Key Points

• CD168 expression correlates with better prognosis in lung adenocarcinoma patients, highlighting its potential as a biomarker.
• A significant association between immune features and CD168 indicates its role in the tumor microenvironment.
• Assessment involved profiling patient data to evaluate the enrichment of the MAPK/ERK pathway related to CD168.
• These findings suggest the need for further exploration of CD168's role in immune responses in lung cancer.